214 related articles for article (PubMed ID: 9334816)
1. Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro.
Simard J; Labrie C; Bélanger A; Gauthier S; Singh SM; Mérand Y; Labrie F
Int J Cancer; 1997 Sep; 73(1):104-12. PubMed ID: 9334816
[TBL] [Abstract][Full Text] [Related]
2. Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells.
Simard J; Sanchez R; Poirier D; Gauthier S; Singh SM; Merand Y; Belanger A; Labrie C; Labrie F
Cancer Res; 1997 Aug; 57(16):3494-7. PubMed ID: 9270018
[TBL] [Abstract][Full Text] [Related]
3. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium.
Labrie F; Labrie C; Bélanger A; Simard J; Gauthier S; Luu-The V; Mérand Y; Giguere V; Candas B; Luo S; Martel C; Singh SM; Fournier M; Coquet A; Richard V; Charbonneau R; Charpenet G; Tremblay A; Tremblay G; Cusan L; Veilleux R
J Steroid Biochem Mol Biol; 1999; 69(1-6):51-84. PubMed ID: 10418981
[TBL] [Abstract][Full Text] [Related]
4. Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells.
Poulin R; Merand Y; Poirier D; Levesque C; Dufour JM; Labrie F
Breast Cancer Res Treat; 1989 Oct; 14(1):65-76. PubMed ID: 2605344
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice.
Gutman M; Couillard S; Roy J; Labrie F; Candas B; Labrie C
Int J Cancer; 2002 May; 99(2):273-8. PubMed ID: 11979444
[TBL] [Abstract][Full Text] [Related]
6. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
Lykkesfeldt AE; Madsen MW; Briand P
Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
[TBL] [Abstract][Full Text] [Related]
7. The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor.
Schafer JI; Liu H; Tonetti DA; Jordan VC
Cancer Res; 1999 Sep; 59(17):4308-13. PubMed ID: 10485477
[TBL] [Abstract][Full Text] [Related]
8. The estrogenic and antiestrogenic activities of droloxifene in human breast cancers.
Kawamura I; Mizota T; Lacey E; Tanaka Y; Manda T; Shimomura K; Kohsaka M
Jpn J Pharmacol; 1993 Sep; 63(1):27-34. PubMed ID: 8271528
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of the antiestrogens EM-800 and tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice.
Couillard S; Gutman M; Labrie C; Bélanger A; Candas B; Labrie F
Cancer Res; 1998 Jan; 58(1):60-4. PubMed ID: 9426058
[TBL] [Abstract][Full Text] [Related]
10. Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors.
Martel C; Provencher L; Li X; St Pierre A; Leblanc G; Gauthier S; Mérand Y; Labrie F
J Steroid Biochem Mol Biol; 1998 Feb; 64(3-4):199-205. PubMed ID: 9605415
[TBL] [Abstract][Full Text] [Related]
11. Induction of transforming growth factor beta by the antiestrogens droloxifene, tamoxifen, and toremifene in MCF-7 cells.
Knabbe C; Zugmaier G; Schmahl M; Dietel M; Lippman ME; Dickson RB
Am J Clin Oncol; 1991; 14 Suppl 2():S15-20. PubMed ID: 1835818
[TBL] [Abstract][Full Text] [Related]
12. Regulation of progesterone-binding breast cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer.
Simard J; Dauvois S; Haagensen DE; Lévesque C; Mérand Y; Labrie F
Endocrinology; 1990 Jun; 126(6):3223-31. PubMed ID: 2351114
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of the new orally active antiestrogen EM-800 with ICI 182 780 and toremifene on estrogen-sensitive parameters in the ovariectomized mouse.
Martel C; Labrie C; Bélanger A; Gauthier S; Mérand Y; Li X; Provencher L; Candas B; Labrie F
Endocrinology; 1998 May; 139(5):2486-92. PubMed ID: 9564862
[TBL] [Abstract][Full Text] [Related]
14. Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines.
Müller V; Jensen EV; Knabbe C
Cancer Res; 1998 Jan; 58(2):263-7. PubMed ID: 9443403
[TBL] [Abstract][Full Text] [Related]
15. Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast-cancer cells.
Coopman P; Garcia M; Brünner N; Derocq D; Clarke R; Rochefort H
Int J Cancer; 1994 Jan; 56(2):295-300. PubMed ID: 8314314
[TBL] [Abstract][Full Text] [Related]
16. EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium.
Labrie F; Labrie C; Bélanger A; Simard J; Giguère V; Tremblay A; Tremblay G
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):213-25. PubMed ID: 11850228
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological activities of thioether derivatives related to the antiestrogens tamoxifen and ICI 164384.
Auger S; Mérand Y; Pelletier JD; Poirier D; Labrie F
J Steroid Biochem Mol Biol; 1995 Jun; 52(6):547-65. PubMed ID: 7779759
[TBL] [Abstract][Full Text] [Related]
18. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
[TBL] [Abstract][Full Text] [Related]
19. Compared effects of GnRH analogs and 4-hydroxytamoxifen on growth and steroid receptors in antiestrogen sensitive and resistant MCF-7 breast cancer cell sublines.
Néri C; Berthois Y; Schatz B; Drieu K; Martin PM
Breast Cancer Res Treat; 1990 Feb; 15(2):85-93. PubMed ID: 2138918
[TBL] [Abstract][Full Text] [Related]
20. ICI 164,384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness.
Thompson EW; Katz D; Shima TB; Wakeling AE; Lippman ME; Dickson RB
Cancer Res; 1989 Dec; 49(24 Pt 1):6929-34. PubMed ID: 2582435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
